Raising the Bar: What to Expect from Cardiovascular Genetic Testing in 2018
May 31, 2018
Webinar information
Date: June 28, 2018
Time: 9:00 AM PST / 18:00 PM CEST
Duration: 1 hour
C.E.U: -
Speaker: Julie Hathaway, Tero-Pekka Alastalo

Date: June 28, 2018
Time: 9:00 AM PST / 18:00 PM CEST

While cardiovascular (CV) genetics was the first subspecialty to introduce large-scale multi-gene panels, it was also the first to experience an important downstream effect. This resulted in a wave of results that, we would soon learn, were not all that they seemed.

The last decade has led cardiovascular genetic testing down a winding and bumpy road.

Multiple efforts have been made over the years to streamline genetic testing: significantly improving testing and interpretation technology, standardizing variant classification, and shedding light on the increasingly recognized “genes of uncertain significance.”

With so many laboratories to choose from, healthcare professionals should have high expectations of the CV genetics offering from these companies.

Genetic Testing for Cardiovascular Diseases

After watching this webinar, you will be better able to navigate your cardiovascular genetic testing options with the end goal of choosing a trustworthy test with the highest likelihood of yielding an informative result for your patient and family.

Key Objectives:

  • Outline the important quality coverage metrics to consider when choosing a cardiovascular gene panel
  • Review the existing limitations in the analysis of certain cardiac-specific genes
  • Demonstrate the steps taken to build a carefully curated, clinically relevant cardiac gene panel

Read more about our options for cardiovascular diseases here.


Webinar video and content: Copyright © 2020 Blueprint Genetics. All trademarks are property of their respective owners.


Tero-Pekka Alastalo

Tero-Pekka is the Executive Director of Medical, and also a co-founder at Blueprint Genetics. He is based in San Francisco and holds various responsibilities in the North American operations of the company. Tero-Pekka has an MD-PhD degree and is specialized in pediatrics and pediatric cardiology. He has a PhD in molecular and cellular biology as well. During his 3-year postdoctoral training at Stanford University School of Medicine, he focused on the molecular genetic mechanisms of cardiovascular disease.

Julie Hathaway

Julie Hathaway, MSc, CGC, CCGC, is a clinical liaison at Blueprint Genetics. She has over 6 years’ experience working in cardiac genetics; her past roles include both program coordinator and genetic counselor in a provincial multidisciplinary inherited arrhythmia program. Julie is an American and Canadian board-certified genetic counselor.

Last modified: October 30, 2020